Welcome, everybody, to Madrid. We are delighted on behalf of our colleagues to update you on the Himalaya study. Wow, can you believe it’s seven years? We’re going to present the seven-year overall survival and overall survival by the tumor response measures for the Himalaya study, if you recall, one dose only of Tremelimumab as NTC LA4 plus monthly treatment with Nivolumab under Atezolizumab or actually Durvalumab...
Welcome, everybody, to Madrid. We are delighted on behalf of our colleagues to update you on the Himalaya study. Wow, can you believe it’s seven years? We’re going to present the seven-year overall survival and overall survival by the tumor response measures for the Himalaya study, if you recall, one dose only of Tremelimumab as NTC LA4 plus monthly treatment with Nivolumab under Atezolizumab or actually Durvalumab. We have found, after looking into the whole participants, 1,200 or close to 1,200 of them, that the overall survival that was reported initially at 16.43 months and compared to the 13.77 for the Sorafenib. At now seven years, or in other words, 84 months, we have 14% survival for the stride regimen, Tremelimumab versus Durvalumab, and a mere 17% for the Sorafenib. So again, the overall survival favors the stride over the Sorafenib after seven years. And to add to this, in regard to the outcome of the patients, number one survival for the ALBI scoring grade one was 23.43 months with the stride, and it was 18.92 months for the Sorafenib, and at 7 years, it was 16% for the ALBI grade 1, and it was 11% for the ALBI grade 2 and 3. So again, one more time, this is the only study that has shown so far 7 years survival outcome in regard to treatment with double checkpoint inhibitors in HCC. And it really proves one more time that this therapy is very active. And wow, this one dose only of Tremelimumab that was given seven years beforehand still is active and doing its effect after seven years. Thanks again for listening.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.